On June 3, Simcere Zaiming announced that SIM0613 initiated a Phase I clinical trial, with the first patient enrolled in China on June 2, 2026. SIM061...

At the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO) held from May 29 to June 2, 2026, Simcere Zaiming will present nine cli...

On May 21, 2026, Simcere Zaiming announced that SIM0532, a pan-RAS-targeted investigational anti-tumor drug independently developed by the company, ha...

May 6, 2026, Simcere Zaiming announces today that SIM0613 for Injection, an LRRC15-targeting antibody-drug conjugate (ADC) independently developed by ...